Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
